Circulating Th17 T cells at treatment onset predict autoimmune toxicity of PI3Kδ inhibitors

PI3Kδ inhibitors are approved for the therapy of B cell malignancies, but their clinical use has been limited by unpredictable autoimmune toxicity, despite promising efficacy and evidence that toxicity is associated with improved clinical outcomes. Prior phenotypic evaluation by CyTOF has identified...

Descripción completa

Detalles Bibliográficos
Autores principales: Gadi, Deepti, Martindale, Stephen P., Chiu, Pui Yan, Khalsa, Jasneet, Chen, Pei-Hsuan, Fernandes, Stacey M., Wang, Zixu, Tyekucheva, Svitlana, Machado, John-Hanson, Fisher, David C., Armand, Philippe, Davids, Matthew S., Rodig, Scott, Sherry, Barbara, Brown, Jennifer R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9895075/
https://www.ncbi.nlm.nih.gov/pubmed/36732326
http://dx.doi.org/10.1038/s41408-023-00788-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9895075/
https://www.ncbi.nlm.nih.gov/pubmed/36732326
http://dx.doi.org/10.1038/s41408-023-00788-9

Ejemplares similares